A Phase 1/2 interventional study of Obinutuzumab and Pinatuzumab Vedotin in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma, sponsored by Genentech, Inc.. Completed at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-21.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing obinutuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 1 of them phase 3. obinutuzumab · Lymphoma, Follicular.
Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, this one is the 3rd largest by enrollment, is one of 3 that started in 2012, is one of 5 in phase 1/2, and was the 4th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →8 of the 30 studies testing obinutuzumab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–90
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Heidelberg University · Sites in Germany
Ages 18+
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 2 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 49 across the 30 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
22 studies in Lymphoma, Follicular by Hoffmann-La Roche: none open now, 2 under way, 1 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Lymphoma, Follicular by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2012, is one of 7 in phase 1/2, and was the 6th registered.
Hoffmann-La Roche’s Lymphoma, Follicular studies by the year they started, since 2004.
6 of the studies testing obinutuzumab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05045664Phase 3Heidelberg UniversityEarly Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody | 2027-09-30 |
| NCT03980171Peter MacCallum Cancer Centre, AustraliaStudy of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | 2026-11 |
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT06549335Ruijin HospitalZanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) | 2026-12-01 |
| NCT04450173University of California, DavisObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | 2027-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, from their registry updates:
Among Hoffmann-La Roche’s 22 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label study will evaluate the safety and efficacy of pinatuzumab vedotin (DCDT2980S) or polatuzumab vedotin (DCDS4501A) in combination with rituximab (RTX), as well as of polatuzumab vedotin in combination with obinutuzumab in participants with relapsed or refractory (r/r) follicular lymphoma (FL) and r/r diffuse large B-cell lymphoma (DLBCL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For the first 2 cycles, RTX 375 milligrams per square meter (mg/m\^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m\^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
Drug: Pinatuzumab Vedotin · Drug: Polatuzumab Vedotin · Drug: Rituximab
For the first 2 cycles, RTX 375 mg/m\^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m\^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
Drug: Pinatuzumab Vedotin · Drug: Polatuzumab Vedotin · Drug: Rituximab
For the first 2 cycles, RTX 375 mg/m\^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
Drug: Polatuzumab Vedotin · Drug: Rituximab
For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
Drug: Obinutuzumab · Drug: Polatuzumab Vedotin
For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
Drug: Obinutuzumab · Drug: Polatuzumab Vedotin
For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
Drug: Obinutuzumab · Drug: Polatuzumab Vedotin
Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
Also known as: GA101, Gazyva, Gazyvaro
Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
Also known as: DCDT2980S
Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
Also known as: DCDS4501A
RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.
Also known as: MabThera/Rituxan
Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments greater than or equal to (\>/=) 4 weeks after initial documentation. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as \>/=50 percent (%) decrease in sum of the products of greatest diameters (SPD) of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a \>/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. Participants with insufficient data to determine response were classified as non-responders.
Time frame: Baseline up to 12 months after the last dose of study treatment (up to approximately 3.5 years)
Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014). DOR was defined as the time from the initial documentation of a CR or PR to the time of PD or death. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as \>/=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a \>/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Time frame: First occurrence of objective response up to PD/relapse or death due to any cause, whichever occurred first (up to approximately 3.5 years)
Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H
Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to \[\</=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \</=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. 90% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against pinatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Time frame: Baseline, post-baseline (up to approximately 5.5 years)
Number of Participants With ADA to Polatuzumab Vedotin
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against polatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Time frame: Baseline, post-baseline (up to approximately 5.5 years)
Number of Participants With ADA to Obinutuzumab
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against obinutuzumab at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
Time frame: Baseline, post-baseline (up to approximately 5.5 years)
Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)
Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)
Percentage of Participants Who Died Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C)
Percentage of participants who died due to any cause was reported.
Time frame: Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)
Overall Survival (OS): Rituximab Containing Regimens (Arms A and B, Cohort C)
OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)
Percentage of Participants With CR at EOT Based on PET/CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Tumor response assessment was performed by the investigator according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by the Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. CR was defined as reduction of longest transverse diameter (LDi) of target nodes/nodal masses to less than or equal to (\</=) 1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. CR was defined as reduction of LDi of target nodes/nodal masses to \</=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to \</=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as \>/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least \>50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to \</=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as \>/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least \>50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 8 Day 1 (cycle length = 21 Days) or last study treatment (maximum up to 27-29 weeks)
Percentage of Participants With Best OR Based on PET/CT or CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H)
Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT or CT scan. Best OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: Baseline up to disease progression or death, whichever occurred first (up to approximately 5.5 years)
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
AUCinf for rituximab was estimated from serum concentration data using non-compartmental analysis.
Time frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)
Maximum Observed Concentration (Cmax) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Cmax for rituximab was estimated from serum concentration data using non-compartmental analysis.
Time frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)
Systemic Clearance (CL) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
CL for rituximab was estimated from serum concentration data using non-compartmental analysis.
Time frame: Pre-infusion (Hour 0) & 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 days)
Half-Life (t1/2) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
t1/2 for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) \& 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, \& 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days).
Time frame: Day 1 up to 1.5 years (detailed timeframe is provided in the Outcome Measure Description)
Volume of Distribution at Steady State (Vss) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C)
Vss for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) \& 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, \& 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days)
Time frame: Day 1 up to 1.5 years (detailed timeframe is provided in the Outcome Measure Description)
AUCinf of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
AUCinf of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with Monomethyl Auristatin E (MMAE)-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of Antibody Conjugated Monomethyl Auristatin E (acMMAE) for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
AUCinf of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. Antibody conjugated MMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Area Under the Concentration-Time Curve From Time Zero To Last Measurable Concentration (AUClast) of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
AUClast of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Cmax of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of acMMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Cmax of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Cmax of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Cmax of Obinutuzumab: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
Cmax of obinutuzumab was estimated from serum concentration data using non-compartmental analysis.
Time frame: Pre-infusion (Hour 0) & 30 minutes Post-infusion (infusion length=30-90 minutes) on Day 1 of Cycle 1; Day 8, Day 15 of Cycle 1 (Cycle length= 21 Days)
Overall Survival (OS): Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G)
OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)
Percentage of Participants Who Died Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)
Percentage of participants who died due to any cause was reported.
Time frame: Baseline up to death due to any cause (from baseline up to study completion date, up to approximately 5.5 years)
Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 5.5 years)
Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G)
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
Time frame: Baseline up to PD or death due to any cause, whichever occurs first (up to approximately 5.5 years)
A total of 289 participants were screened, out of which, 231 participants were enrolled into the study.
| Milestone | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|---|---|
| Started | 63 | 59 | 20 | 9 | 40 | 40 |
| Completed | 16 | 15 | 11 | 4 | 26 | 5 |
| Not completed | 47 | 44 | 9 | 5 | 14 | 35 |
| Withdrew: Death | 34 | 32 | 6 | 3 | 8 | 31 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Progression of disease | 1 | 2 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 8 | 2 | 1 | 3 | 3 |
| Withdrew: Non-compliance | 0 | 0 | 0 | 0 | 1 | 0 |
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments greater than or equal to (\>/=) 4 weeks after initial documentation. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as \>/=50 percent (%) decrease in sum of the products of greatest diameters (SPD) of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a \>/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. Participants with insufficient data to determine response were classified as non-responders.
| percentage of participants | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | 59.5 (45.67 to 72.32) | 61.9 (41.72 to 79.43) | 53.8 (39.58 to 67.65) | 70.0 (49.22 to 86.04) | 75.0 (54.44 to 89.59) |
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014). DOR was defined as the time from the initial documentation of a CR or PR to the time of PD or death. CR was defined as disappearance of all clinical/radiographic evidence of disease, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. PR was defined as \>/=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a \>/=50% decrease in SPD of hepatic and splenic nodules, absence of other organ involvement, and no new sites of disease. PD was defined as appearance of any new lesion more than 1.5 centimeters (cm) in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
| months | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | 6.24 (0.89 to 22.57) | 6.47 (0.03 to 23.52) | 13.37 (0.03 to 35.68) | 9.36 (0.03 to 19.35) | 12.85 (0.03 to 22.11) |
Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to \[\</=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \</=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. 90% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E (DLBCL): Obinutuzumab + Polatuzumab | Cohort E (FL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|
| Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H | 0 (0.00 to 52.71) | 50.0 (2.53 to 97.47) | 35.3 (21.79 to 50.82) | 0 (0.00 to 10.50) |
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against pinatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
| participants | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| Baseline | 2 | — |
| Post-baseline | 0 | 0 |
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against polatuzumab vedotin at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
| participants | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|---|---|
| Baseline | — | 1 | 0 | 0 | 0 | 0 |
| Post-baseline | 0 | 0 | 0 | 0 | 0 | 0 |
Participants provided blood samples for evaluation of ADA. The number of participants with positive results for ADA against obinutuzumab at Baseline and at any of the post-baseline assessment time-points (overall 1.5 years) was reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result.
| participants | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|
| Baseline | 1 | 2 | 0 |
| Post-baseline | 0 | 0 | 0 |
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
| percentage of participants | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C) | 85.7 | 52.4 | 76.9 | 55.0 | 60.0 |
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | 5.388 (3.943 to 10.579) | 12.682 (8.936 to 27.466) | 5.552 (4.304 to 12.780) | 15.277 (12.189 to 25.133) | 18.103 (11.598 to 30.259) |
Percentage of participants who died due to any cause was reported.
| percentage of participants | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Percentage of Participants Who Died Due to Any Cause: Rituximab Containing Regimens (Arms A and B, Cohort C) | 66.7 | 23.8 | 61.5 | 15.0 | 20.0 |
OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Overall Survival (OS): Rituximab Containing Regimens (Arms A and B, Cohort C) | 16.493 (7.458 to 32.460) | NA (44.025 to NA) | 18.760 (10.415 to 38.571) | NA (NA to NA) | NA (NA to NA) |
Tumor response assessment was performed by the investigator according to modified Lugano classification using PET/CT scan. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E (DLBCL): Obinutuzumab + Polatuzumab | Cohort E (FL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|
| Percentage of Participants With CR at EOT Based on PET/CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) | 25.0 (1.27 to 75.14) | 66.7 (13.54 to 98.30) | 33.3 (20.49 to 48.34) | 15.2 (6.17 to 29.25) |
Tumor response assessment was performed by an IRC according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E (DLBCL): Obinutuzumab + Polatuzumab | Cohort E (FL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|
| Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) | 25.0 (1.27 to 75.14) | 100.0 (22.36 to 100.00) | 64.7 (49.18 to 78.21) | 18.5 (7.59 to 35.06) |
Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT scan. OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E (DLBCL): Obinutuzumab + Polatuzumab | Cohort E (FL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|
| Percentage of Participants With OR at EOT Based on PET/CT Assessment as Determined by the Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) | 25.0 (1.27 to 75.14) | 66.7 (13.54 to 98.30) | 63.9 (48.83 to 77.15) | 21.2 (10.40 to 36.18) |
Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. CR was defined as reduction of longest transverse diameter (LDi) of target nodes/nodal masses to less than or equal to (\</=) 1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) | 6.5 (1.2 to 19.0) | 13.9 (5.6 to 27.0) |
Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. CR was defined as reduction of LDi of target nodes/nodal masses to \</=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Percentage of Participants With CR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) | 10.8 (3.8 to 23.1) | 20.5 (10.6 to 34.0) |
Tumor response assessment was performed by an IRC according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to \</=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as \>/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least \>50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by IRC Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) | 25.8 (13.5 to 41.8) | 66.7 (51.7 to 79.5) |
Tumor response assessment was performed by investigator according to modified Lugano classification using CT scan. OR was defined as a response of CR or PR. CR was defined as reduction of LDi of target nodes/nodal masses to \</=1.5 cm, no extralymphatic sites of disease, absence of non-measured lesions and new lesions, reduction of enlarged organs to normal, and normal/IHC-negative bone marrow morphology. PR was defined as \>/=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen by at least \>50% beyond normal; and no new lesions. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Percentage of Participants With OR at EOT Based on CT Assessment Alone as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) | 21.6 (11.2 to 35.6) | 64.1 (49.7 to 76.8) |
Tumor response assessment was performed by investigator according to modified Lugano classification using PET/CT or CT scan. Best OR was defined as a response of CR or PR. CR was defined as a score of 1 (no uptake above background), 2 (uptake \</=mediastinum), or 3 (uptake \<mediastinum but \</=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow; and normal/IHC-negative bone marrow morphology. PR was defined as a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites; no new lesions; and reduced residual uptake in bone marrow compared with baseline. 90% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Cohort E (DLBCL): Obinutuzumab + Polatuzumab | Cohort E (FL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|
| Percentage of Participants With Best OR Based on PET/CT or CT Assessment as Determined by Investigator Per Lugano 2014 Response Criteria: Obinutuzumab-Containing Cohorts (Cohorts E, G, and H) | 20.0 (1.02 to 65.74) | 50.0 (9.76 to 90.24) | 74.4 (60.40 to 85.38) | 43.6 (30.00 to 57.94) |
AUCinf for rituximab was estimated from serum concentration data using non-compartmental analysis.
| day*micrograms (mcg)/milliliter (mL) | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) | 5640 ± 8320 | 3350 ± 1180 | 4200 ± 2620 | 3910 ± 2480 | 2660 ± 879 |
Cmax for rituximab was estimated from serum concentration data using non-compartmental analysis.
| mcg/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) | 217 ± 61.5 | 225 ± 40.9 | 232 ± 72.7 | 228 ± 83.3 | 227 ± 32.4 |
CL for rituximab was estimated from serum concentration data using non-compartmental analysis.
| mL/day/meter-square (m^2) | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Systemic Clearance (CL) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) | 113.97 ± 61.41 | 124.53 ± 41.12 | 116.26 ± 59.99 | 134.31 ± 97.45 | 158.57 ± 60.47 |
t1/2 for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) \& 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, \& 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days).
| days | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Half-Life (t1/2) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) | 35.3 ± 56.3 | 18.7 ± 6.23 | 25.6 ± 18.0 | 19.8 ± 7.34 | 14.4 ± 3.62 |
Vss for rituximab was estimated from serum concentration data using non-compartmental analysis. Time Frame: Pre-infusion (Hour 0) \& 30 minutes post-infusion (infusion length= 2-6 hours) on Day 1 of Cycle 1-4 and every 4th Cycle thereafter (approximately up to 1.5 years); Day 8, Day 15 of Cycle 1 and 3; 30 Days after last infusion; 2, 4, \& 6 months after treatment completion visit (approximately up to 1.5 years, Cycle length= 21 days)
| mL/m^2 | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab |
|---|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of Rituximab: Rituximab Containing Regimens (Arms A and B, Cohort C) | 2901.85 ± 1009.31 | 2802.96 ± 678.33 | 2988.90 ± 788.89 | 2839.26 ± 730.10 | 2654.46 ± 413.19 |
AUCinf of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with Monomethyl Auristatin E (MMAE)-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| day*mcg/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab |
|---|---|---|
| AUCinf of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 309 ± 67.7 | 315 ± 111 |
AUCinf of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. Antibody conjugated MMAE is the total concentration of MMAE that was conjugated to the antibody.
| day*nanogram (ng)/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab |
|---|---|---|
| AUCinf of Antibody Conjugated Monomethyl Auristatin E (acMMAE) for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 2840 ± 555 | 3110 ± 828 |
AUClast of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| day*ng/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab |
|---|---|---|
| Area Under the Concentration-Time Curve From Time Zero To Last Measurable Concentration (AUClast) of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 34.2 ± 24.0 | 33.5 ± 17.5 |
Cmax of total antibody for pinatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| mcg/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab |
|---|---|---|
| Cmax of Total Antibody for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 42.5 ± 11.6 | 48.3 ± 9.34 |
Cmax of acMMAE for pinatuzumab was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| ng/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab |
|---|---|---|
| Cmax of acMMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 850 ± 222 | 994 ± 190 |
Cmax of unconjugated MMAE was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| ng/mL | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab |
|---|---|---|
| Cmax of Unconjugated MMAE for Pinatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 4.39 ± 3.15 | 4.20 ± 2.32 |
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| day*mcg/mL | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 412 ± 108 | 428 ± 106 |
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| day*ng/mL | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 3660 ± 843 | 3510 ± 1160 |
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| day*ng/mL | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 31.7 ± 17.2 | 29.5 ± 25.0 |
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| mcg/mL | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 51.9 ± 12.3 | 55.9 ± 12.8 |
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| ng/mL | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 948 ± 204 | 968 ± 268 |
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| ng/mL | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab |
|---|---|---|
| Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 2.4 mg/kg Given in Combination With Rituximab | 3.72 ± 1.98 | 3.29 ± 2.71 |
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| day*mcg/mL | Cohort C (FL): RTX + Polatuzumab |
|---|---|
| AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab | 258 ± 84.1 |
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| day*ng/mL | Cohort C (FL): RTX + Polatuzumab |
|---|---|
| AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab | 2600 ± 630 |
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| day*ng/mL | Cohort C (FL): RTX + Polatuzumab |
|---|---|
| AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab | 17.7 ± 9.39 |
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| mcg/mL | Cohort C (FL): RTX + Polatuzumab |
|---|---|
| Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab | 42.2 ± 7.92 |
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| ng/mL | Cohort C (FL): RTX + Polatuzumab |
|---|---|
| Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab | 787 ± 113 |
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| ng/mL | Cohort C (FL): RTX + Polatuzumab |
|---|---|
| Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Rituximab | 2.02 ± 1.34 |
AUCinf of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| day*mcg/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| AUCinf of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab | 218 ± 89.1 | 215 ± 102 |
AUCinf of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| day*ng/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| AUCinf of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab | 2440 ± 665 | 2340 ± 875 |
AUClast of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| day*ng/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| AUClast of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab | 27.9 ± 21.3 | 22.3 ± 9.46 |
Cmax of total antibody for polatuzumab vedotin was estimated from serum concentration data using non-compartmental analysis. Total antibody is defined as antibody with MMAE-to-antibody ratio equal or greater than zero, including fully conjugated, partially unconjugated, and fully unconjugated antibody.
| mcg/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Cmax of Total Antibody for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab | 35.0 ± 9.89 | 34.2 ± 7.89 |
Cmax of acMMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. acMMAE is the total concentration of MMAE that was conjugated to the antibody.
| ng/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Cmax of acMMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab | 711 ± 155 | 694 ± 161 |
Cmax of Unconjugated MMAE for polatuzumab vedotin was estimated from plasma concentration data using non-compartmental analysis. Unconjugated MMAE is the total concentration of MMAE that was not conjugated to the antibody.
| ng/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Cmax of Unconjugated MMAE for Polatuzumab Vedotin at Dose Level 1.8 mg/kg Given in Combination With Obinutuzumab | 3.62 ± 3.73 | 2.80 ± 1.30 |
Cmax of obinutuzumab was estimated from serum concentration data using non-compartmental analysis.
| mcg/mL | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Cmax of Obinutuzumab: Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) | 340 ± 95.0 | 330 ± 87.9 |
OS was defined as the time from the date of randomization or enrollment to the date of death from any cause. The median OS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
| Months | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Overall Survival (OS): Obinutuzumab-Containing Cohorts (Cohorts E + H and E + G) | 10.5 (5.5 to 16.7) | NA (38.4 to NA) |
Percentage of participants who died due to any cause was reported.
| percentage of participants | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Percentage of Participants Who Died Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G) | 77.8 | 20.5 |
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node. PFS was defined as the time from the date of randomization to the date of PD or death from any cause, whichever occurred first. In absence of PD or death, PFS was censored at the date of the last tumor assessment. Participants with no post-baseline tumor assessment were censored on the date of randomization or date of enrollment. The median PFS was estimated using Kaplan-Meier estimates and the 95% CI for median was computed using the method of Brookmeyer and Crowley.
| months | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Progression-free Survival (PFS) as Determined by Modified Response and Progression Criteria for NHL: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G) | 2.7 (2.1 to 5.9) | 19.5 (10.9 to 38.4) |
Tumor response was evaluated according to modified response and progression criteria for NHL published by Cheson et al (2007 and 2014) and confirmed by repeat assessments \>/=4 weeks after initial documentation. PD was defined as appearance of any new lesion more than 1.5 cm in any axis, at least a 50% increase from nadir in the SPD or longest diameter of any previous lesion or node.
| percentage of participants | Cohort E + Cohort H (DLBCL): Obinutuzumab + Polatuzumab | Cohort E + Cohort G (FL): Obinutuzumab + Polatuzumab |
|---|---|---|
| Percentage of Participants With PD as Determined by Modified Response and Progression Criteria for NHL or Death Due to Any Cause: Obinutuzumab Containing Cohorts (Cohorts E + H and E + G) | 88.9 | 56.8 |
Collected over Baseline up to 30 days after the last dose of study treatment (up to approximately 12 months for rituximab-containing regimens [Arms A and B, Cohort C] and 24 weeks for Cohorts E, G, and H). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 35/63 (55.6%) | 27/63 (42.9%) | 63/63 (100%) |
| Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 33/59 (55.9%) | 21/59 (35.6%) | 58/59 (98.3%) |
| Cohort C (FL): RTX + Polatuzumab | 6/20 (30%) | 8/20 (40%) | 20/20 (100%) |
| Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 4/9 (44.4%) | 3/9 (33.3%) | 9/9 (100%) |
| Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 8/40 (20%) | 9/40 (22.5%) | 37/40 (92.5%) |
| Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 32/40 (80%) | 18/40 (45%) | 38/40 (95%) |
| Event | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|---|---|
| Pericardial effusionCardiac disorders | 0/63 | 0/59 | 1/20 | 1/9 | 0/40 | 0/40 |
| Gastric perforationGastrointestinal disorders | 0/63 | 0/59 | 0/20 | 1/9 | 0/40 | 0/40 |
| SinusitisInfections and infestations | 0/63 | 0/59 | 0/20 | 1/9 | 0/40 | 0/40 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/63 | 0/59 | 0/20 | 1/9 | 0/40 | 2/40 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/63 | 2/59 | 2/20 | 0/9 | 0/40 | 1/40 |
| Abdominal pain lowerGastrointestinal disorders | 0/63 | 0/59 | 1/20 | 0/9 | 0/40 | 0/40 |
| ConstipationGastrointestinal disorders | 0/63 | 0/59 | 1/20 | 0/9 | 0/40 | 0/40 |
| DiarrhoeaGastrointestinal disorders | 0/63 | 1/59 | 1/20 | 0/9 | 0/40 | 0/40 |
| DysphagiaGastrointestinal disorders | 0/63 | 0/59 | 0/20 | 0/9 | 0/40 | 2/40 |
| PyrexiaGeneral disorders | 2/63 | 1/59 | 1/20 | 0/9 | 0/40 | 0/40 |
| Event | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 32/63 | 34/59 | 13/20 | 5/9 | 18/40 | 9/40 |
| NauseaGastrointestinal disorders | 20/63 | 25/59 | 11/20 | 0/9 | 11/40 | 14/40 |
| Peripheral sensory neuropathyNervous system disorders | 16/63 | 17/59 | 11/20 | 2/9 | 7/40 | 2/40 |
| Neuropathy peripheralNervous system disorders | 23/63 | 27/59 | 6/20 | 1/9 | 8/40 | 8/40 |
| NeutropeniaBlood and lymphatic system disorders | 19/63 | 15/59 | 8/20 | 4/9 | 8/40 | 8/40 |
| DiarrhoeaGastrointestinal disorders | 28/63 | 25/59 | 5/20 | 3/9 | 13/40 | 14/40 |
| ConstipationGastrointestinal disorders | 18/63 | 14/59 | 5/20 | 0/9 | 14/40 | 8/40 |
| HeadacheNervous system disorders | 10/63 | 8/59 | 6/20 | 1/9 | 10/40 | 6/40 |
| Decreased appetiteMetabolism and nutrition disorders | 13/63 | 17/59 | 4/20 | 0/9 | 7/40 | 5/40 |
| AstheniaGeneral disorders | 11/63 | 16/59 | 0/20 | 1/9 | 3/40 | 8/40 |
Analysis was performed on safety-evaluable population, which included all participants who received at least 1 dose of all study treatment.
| Age, Categorical(Participants) | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 25 | 12 | 4 | 23 | 16 | 109 |
| >=65 years | 34 | 34 | 8 | 5 | 17 | 24 | 122 |
| Sex: Female, Male(Participants) | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | Total |
|---|---|---|---|---|---|---|---|
| Female | 27 | 24 | 8 | 2 | 16 | 18 | 95 |
| Male | 36 | 35 | 12 | 7 | 24 | 22 | 136 |
| Ethnicity (NIH/OMB)(Participants) | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Cohort C (FL): RTX + Polatuzumab | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 1 | 0 | 0 | 2 | 10 |
| Not Hispanic or Latino | 48 | 44 | 19 | 9 | 33 | 36 | 189 |
| Unknown or Not Reported | 13 | 10 | 0 | 0 | 7 | 2 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2012 to primary completion in Mar 2017, 53 months.
Results were first posted in Apr 2018, 1 year 1 month after primary completion.
Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's 53 months is below that.
Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab